Thermo Fisher Scientific (TMO)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NYSE]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (Cboe BZX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NYSE]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
for [[ item.sessionDateDisplayLong ]]
Fiscal Year End Date: 12/31
| 03-2016 | 12-2015 | 09-2015 | 06-2015 | 03-2015 | |
| Assets | |||||
| Current Assets | |||||
| Cash & Cash Equivalents | 826,800 | 452,100 | 503,400 | 768,400 | 864,600 |
| Marketable Securities | N/A | N/A | N/A | 2,000 | 8,400 |
| Receivables | 2,668,300 | 2,763,000 | 2,543,900 | 2,631,000 | 2,538,000 |
| Inventories | 2,154,900 | 1,991,700 | 1,987,200 | 1,962,300 | 1,898,800 |
| Income taxes - deferred | N/A | N/A | 263,300 | 283,500 | 299,400 |
| Other current assets | 889,000 | 534,400 | 728,100 | 589,400 | 571,300 |
| TOTAL | $6,539,000 | $5,741,200 | $6,025,900 | $6,236,600 | $6,180,500 |
| Non-Current Assets | |||||
| PPE Net | 2,483,100 | 2,448,800 | 2,392,200 | 2,406,900 | 2,384,200 |
| Intangibles | 32,870,300 | 31,585,900 | 31,761,400 | 32,190,600 | 32,355,400 |
| Other Non-Current Assets | 1,060,300 | 1,058,400 | 967,600 | 940,300 | 937,200 |
| TOTAL | $36,413,700 | $35,093,100 | $35,121,200 | $35,537,800 | $35,676,800 |
| Total Assets | $42,952,700 | $40,834,300 | $41,147,100 | $41,774,400 | $41,857,300 |
| Liabilities | |||||
| Current Liabilities | |||||
| Accounts payable and accrued liabilities | 853,000 | 822,200 | 783,300 | 819,000 | 827,600 |
| Accrued Expenses | 421,200 | 598,200 | 549,300 | 478,500 | 486,900 |
| TOTAL | $6,322,800 | $4,146,300 | $5,735,100 | $6,100,400 | $6,861,000 |
| Non-Current Liabilities | |||||
| Long Term Debt | 11,653,000 | 11,420,200 | 10,277,900 | 10,663,700 | 10,696,200 |
| Deferred Revenues | 360,500 | 317,900 | 320,900 | 334,300 | 332,900 |
| Other Non-Current Liabilities | 1,358,500 | 1,295,000 | 1,252,200 | 1,195,600 | 1,162,400 |
| TOTAL | $15,705,500 | $15,337,800 | $14,561,800 | $14,994,200 | $15,081,500 |
| Total Liabilities | $22,028,300 | $19,484,100 | $20,296,900 | $21,094,600 | $21,942,500 |
| Shareholders' Equity | |||||
| Shares Outstanding, K | 393,512 | 396,262 | 399,098 | 398,488 | 398,057 |
| Common Shares | 413,300 | 411,900 | 411,400 | 410,600 | 410,200 |
| Retained earnings | 12,485,200 | 12,142,300 | 11,599,700 | 11,183,700 | 10,732,100 |
| Other shareholders' equity | -1,866,900 | -1,997,200 | -1,886,700 | -1,594,800 | -1,846,800 |
| TOTAL | $20,924,400 | $21,350,200 | $20,850,200 | $20,679,800 | $19,914,800 |
| Total Liabilities And Equity | $42,952,700 | $40,834,300 | $41,147,100 | $41,774,400 | $41,857,300 |